Analysts Set Vera Therapeutics, Inc. (NASDAQ:VERA) Price Target at $65.44

Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) have earned an average rating of “Buy” from the ten research firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation, six have issued a buy recommendation and three have issued a strong buy recommendation on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $65.44.

A number of analysts recently issued reports on VERA shares. Wells Fargo & Company began coverage on Vera Therapeutics in a research note on Thursday, November 21st. They set an “overweight” rating and a $70.00 price objective on the stock. The Goldman Sachs Group started coverage on Vera Therapeutics in a report on Tuesday, January 28th. They set a “buy” rating and a $58.00 target price for the company. Wolfe Research assumed coverage on shares of Vera Therapeutics in a report on Tuesday, February 4th. They issued an “outperform” rating and a $49.00 price target on the stock. JPMorgan Chase & Co. raised their price objective on shares of Vera Therapeutics from $72.00 to $75.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. Finally, Guggenheim upped their target price on shares of Vera Therapeutics from $56.00 to $64.00 and gave the stock a “buy” rating in a report on Monday, October 28th.

Vera Therapeutics Trading Down 19.7 %

Shares of VERA stock opened at $27.46 on Friday. The stock has a market capitalization of $1.74 billion, a price-to-earnings ratio of -10.52 and a beta of 1.11. The company’s fifty day simple moving average is $38.51 and its two-hundred day simple moving average is $40.85. Vera Therapeutics has a 1 year low of $25.99 and a 1 year high of $51.61. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76.

Insider Buying and Selling

In other news, CEO Marshall Fordyce sold 17,500 shares of Vera Therapeutics stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $43.07, for a total transaction of $753,725.00. Following the completion of the sale, the chief executive officer now directly owns 85,942 shares of the company’s stock, valued at approximately $3,701,521.94. The trade was a 16.92 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last three months, insiders have sold 52,500 shares of company stock worth $2,305,625. Insiders own 21.70% of the company’s stock.

Institutional Investors Weigh In On Vera Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Avoro Capital Advisors LLC boosted its holdings in shares of Vera Therapeutics by 30.2% in the 4th quarter. Avoro Capital Advisors LLC now owns 5,610,000 shares of the company’s stock worth $237,247,000 after purchasing an additional 1,300,410 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in Vera Therapeutics by 11.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,377,049 shares of the company’s stock worth $185,107,000 after buying an additional 437,940 shares during the last quarter. FMR LLC boosted its stake in Vera Therapeutics by 9.6% in the fourth quarter. FMR LLC now owns 3,053,126 shares of the company’s stock worth $129,117,000 after buying an additional 267,842 shares in the last quarter. Vanguard Group Inc. boosted its stake in Vera Therapeutics by 14.3% in the fourth quarter. Vanguard Group Inc. now owns 2,949,564 shares of the company’s stock worth $124,737,000 after buying an additional 369,387 shares in the last quarter. Finally, Holocene Advisors LP grew its position in Vera Therapeutics by 8.8% during the third quarter. Holocene Advisors LP now owns 1,954,528 shares of the company’s stock valued at $86,390,000 after acquiring an additional 158,451 shares during the last quarter. Hedge funds and other institutional investors own 99.21% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.